Back

Low apolipoprotein a1 is significantly associated with decreased risk of cardiovascular events in anticoagulated patients with atrial fibrillation: insights from the ARISTOTLE trial.

26 August 2017 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster session 4 - Atrial fibrillation obesity Atrial fibrillation (AF) ESC Premium Access ESC Congress 2017

About the speaker

Photo
Doctor Tymon Pol

Uppsala University, Uppsala (Sweden)

14 More presentations in this session

Presentation thumbnail
Alogliptin, a DPP-4 inhibitor, alleviates atrial remodeling and improves mitochondrial function and biogenesis in diabetic rabbits
Doctor T. Liu (Tianjin, CN)
Presentation thumbnail
Risk of atrial fibrillation in heart failure with preserved ejection fraction: results from the treatment of cardiac function with an aldosterone antagonist (TOPCAT) Study
Ms J. Neefs (Amsterdam, NL)
Abstract
Presentation thumbnail
C(-915)G polymorphism gene of transforming growth factor 1 in patients with metabolic syndrome and atrial fibrillation
Assistant Professor V. Ionin (Saint Petersburg, RU)
Abstract Slides
Presentation thumbnail
Epicardial obesity as a significant predictor of atrial fibrillation
Doctor A. Ott (Barnaul, RU)
Abstract Slides
Presentation thumbnail
Impact of body mass index in newly diagnosed atrial fibrillation in the GARFIELD-AF registry
Doctor S. Goldhaber (Boston, US)
Abstract Slides

Access the full session

Session thumbnail
Poster session 4 - Atrial fibrillation obesity

The Event

Event poster

ESC Congress 2017

26 August - 30 August 2017

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources